


Dr. Eliezer Van Allen, MD
Dr. Eliezer Van Allen, MD is a medical oncologist in Boston, MA and has over 15 years of experience in the medical field. He graduated from UNIVERSITY OF CALIFORNIA AT LOS ANGELES / CENTER FOR HEALTH SCIENCES in 2007. He is affiliated with medical facilities such as North Shore Medical Center and Brigham and Women's Hospital. He is accepting new patients.
Dana-Farber Cancer Institute
450 Brookline Ave Boston, MA 02215Make an Appointment
Compare with other Medical Oncologists
Compare Dr. Van Allen with our nearby Medical Oncologists at Lawrence Memorial Hospital of Medford.
Make an appointment at Lawrence Memorial Hospital of Medford today at
(781) 334-8748.
Experience Check
Search for experience in a specific area
Dr. Van Allen's Reviews
Likelihood to recommend Dr. Van Allen
5.0
5 Star | 100% | 100% |
4 Star | 0% | 0% |
3 Star | 0% | 0% |
2 Star | 0% | 0% |
1 Star | 0% | 0% |
Overall Patient Satisfaction
Likelihood of recommending Dr. Van Allen to family and friends is 5 out of 5
About Me
biography
Dr. Eliezer Van Allen, MD is a medical oncologist in Boston, MA and has over 15 years of experience in the medical field. He graduated from UNIVERSITY OF CALIFORNIA AT LOS ANGELES / CENTER FOR HEALTH SCIENCES in 2007. He is affiliated with medical...read moreMedical Oncology
*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.
University Of California At Los Angeles / Center For Health Sciences
Medical School, 2007
Healthgrades receives board action history for physicians and physician assistants. The information displayed here is sourced from independent information providers, such as state board websites, and may not be the most up-to-date information. Healthgrades makes no representations with respect to the accuracy of any information provided here and assumes no responsibility or liability for such information.
Learn more about medical license public record checkGenomic Evolution After Chemoradiotherapy in Anal Squamous Cell Carcinoma, 2016-11-16
Biologically informed deep neural network for prostate cancer discovery, 2021-09-22
LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade, 2018-06-21
Transcriptional mediators of treatment resistance in lethal prostate cancer, 2021-03-04
Patterns of structural variation define prostate cancer across disease states, 2022-09-08
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma, 2021-02-05
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, 2015-09-10
Intron retention is a source of neoepitopes in cancer, 2018-08-16
Tumor Evolution: A Problem of Histocompatibility, 2017-11-30
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer, 2017-12-19
Integrated molecular drivers coordinate biological and clinical states in melanoma, 2020-11-23
Genomic evolutionary patterns of leiomyosarcoma and liposarcoma, 2019-06-04
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade, 2018-11-01
Ex VivoProfiling of PD-1 Blockade Using Organotypic Tumor Spheroids, 2017-11-03
Next-generation sequencing to guide cancer therapy, 2015-07-29
Scaling computational genomics to millions of individuals with GPUs, 2019-11-01
Divergent clonal evolution of castration resistant neuroendocrine prostate cancer, 2016-02-08
Genetic effect of chemotherapy exposure in children of testicular cancer survivors, 2015-12-02
Interplay of Mendelian and polygenic risk factors in Arab breast cancer patients, 2023-09-01
Discovery and features of an alkylating signature in colorectal cancer, 2021-06-17
Integrative clinical genomics of advanced prostate cancer, 2015-05-21
Delivering on the promise of precision cancer medicine, 2016-10-25
A patient-driven clinicogenomic partnership for metastatic prostate cancer, 2022-08-19
Genomic evolution and chemoresistance in germ-cell tumours, 2016-11-30
Germline Features Associated with Immune Infiltration in Solid Tumors, 2020-03-03
Evolution of Delayed Resistance to Immunotherapy in a Melanoma Responder, 2021-05-03
Assessing the clinical utility of cancer genomic and proteomic data across tumor types, 2014-06-22
Metabolomic adaptations and correlates of survival to immune checkpoint blockade, 2019-09-25
Systematic auditing is essential to debiasing machine learning in biology, 2021-02-10
Oncogenic Signaling Pathways in The Cancer Genome Atlas, 2018-04-05
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq, 2016-04-08
The long tail of oncogenic drivers in prostate cancer, 2018-04-02
Genomic correlates of response to immune checkpoint blockade, 2019-03-06
Genomic Approaches to Understanding Response and Resistance to Immunotherapy, 2016-10-03
Focus on Breast Cancer
Insurance Check
Search for your insurance carrier and choose your plan type
Locations
Dana-Farber Cancer Institute
Affiliated Hospitals
- Recipient of 31
hospital awardsAmerica's 250 Best Hospitals Award™ (2025)
Top in the nation for overall patient experience based on nine measures related to doctor and nurse communication, hospital cleanliness and noise levels, and medication and post-discharge care instructions
View all awardsOutstanding Patient Experience Award™ (2024, 2023, 2022)
Top in the nation for overall patient experience based on nine measures related to doctor and nurse communication, hospital cleanliness and noise levels, and medication and post-discharge care instructions
View all patient feedbackHow patients felt about the care they received at this hospital.
91%Patients said they were given information about recovering at home7% higher than the national average
84%Patients said that nurses always listened to them and explained things well9% higher than the national average
- Recipient of 28
hospital awardsPatient Safety Excellence Award™ (2025)
Top in the nation for providing excellence in patient safety by preventing infections, medical errors, and other preventable complications
View all awardsSurgical Care Excellence Award™ (2025)
Top in the nation for providing excellence in patient safety by preventing infections, medical errors, and other preventable complications
View all patient feedbackHow patients felt about the care they received at this hospital.
89%Patients said they were given information about recovering at home5% higher than the national average
82%Patients said that nurses always listened to them and explained things well7% higher than the national average
- Recipient of 15
hospital awardsAmerica's 250 Best Hospitals Award™ (2025, 2024)
Top in the nation for providing excellence in patient safety by preventing infections, medical errors, and other preventable complications
View all awardsPatient Safety Excellence Award™ (2024)
Top in the nation for providing excellence in patient safety by preventing infections, medical errors, and other preventable complications
View all patient feedbackHow patients felt about the care they received at this hospital.
89%Patients said they were given information about recovering at home5% higher than the national average
83%Patients said that doctors always listened to them and explained things well7% higher than the national average
Compare with other Medical Oncologists
Compare Dr. Van Allen with our nearby Medical Oncologists at Lawrence Memorial Hospital of Medford.
Make an appointment at Lawrence Memorial Hospital of Medford today at
(781) 334-8748.
Leave a review
How was your experience with Dr. Van Allen?